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Alterations of epigenetic marks are thought to play an important
role in myeloid malignancies. In particular, aberrant DNA
methylation is a hallmark of these diseases. DNMT3A and
DNMT3B methyltransferases have predominant role in de novo
methylation of DNA. Mutations in DNMT3A have been found in
roughly 20% of acute myeloid leukemia (AML).
1–3 The precise
mechanism by which DNMT3A may affect DNA methylation is
not known. The TET2 gene encodes an enzyme that favors the
transformation of 5-methylcytosines in 5-hydroxymethylcyto-
sines. TET2 function requires alpha-ketoglutarate (aKG). TET2 is
frequently mutated in myeloid diseases. Mutation in IDH1 and
IDH2 changes their enzymatic activity and induces an
hypermethylation of AML DNA.
3 Mutated IDH1/2 enzymes
catalyze aKG into 2-hydroxyglutarate (2HG). Production of
2HG impairs TET2 function. This explains why mutations in
TET2 and in IDH1/2 are mutually exclusive.
4 In contrast,
mutations in IDH1/2 are more frequent in AML cases with
DNMT3A mutations.
2
We searched for mutations and deletions of DNMT3A, TET2
and IDH1/2 in a series of 201 chronic myeloid diseases
including 135 myeloproliferative neoplasms (MPNs) and 66
myelodysplastic syndromes (MDSs). The MPN cases comprised
33 polycythemia vera (PV) and 5 post-PV myeloﬁbrosis (MF), 56
essential thrombocythemia (ET) and 10 post-ET MF, 25 primary
myeloﬁbrosis (PMF), 3 MPN- unclassiﬁable and 3 MDS/MPN
cases. The MDSs comprised 5 refractory anemia (RA), 13 RA
with ring sideroblasts (RARS), 7 refractory cytopenia with
multilineage dysplasia, 16 RA with excess blasts (RAEB) type 1,
20 RAEB type 2 and 5 MDS-unclassiﬁable cases.
We determined the sequence of all exons of TET2, exons 4 of
IDH1 and IDH2, and exons 15 to 23 of DNMT3A (which
encode the C-terminal half of the protein, including the catalytic
domain, where most mutations have been found so far), as
described.
2,5 High density array-comparative genomic hybridi-
zation
5 provided information on the status of the respective loci.
In MPNs, we found 13 mutations in TET2 in 12 patients (2 PV,
1 post-PV MF, 3 ET, 2 post-ET MF, 2 PMF, and 2 MDS/MPN one
of which had two mutations), 0 mutations in IDH1/2, and
2 mutations in DNMT3A (1 in a JAK2 V617F-positive PV, 1 in a
JAK2 V617F-negative PMF) (see Table 1). The two mutations in
DNMT3A were missense (c.2245C4T, p.Arg749Cys in the PV;
c.2644G4A, p.Arg882Ser in the PMF). All mutations were
heterozygous.
In MDSs, we found 12 mutations and 1 deletion of TET2 (all
heterozygous), 5 mutations of IDH1/2, and 4 mutations (6%) and
1 deletion of DNMT3A (all heterozygous) (see Table 1). Mutations
in DNMT3A were 1 nonsense (c.1681G4T, p.Glu561Stop), 1
frameshift (c.1872del, p.Pro625LeufsX26) and 2 missense
(c.1723G4C, p.Ala575Pro; c.2141C4G, p.Ser714Cys). Muta-
tions in TET2, IDH1/2 and DNMT3A were all mutually exclusive.
Thus, 23 MDS cases out of 66 (roughly one-third) showed one
alteration (mutation or deletion) in either DNA methylation-
associated gene. Strikingly, the 4 DNMT3A-mutated cases were
1 RA and 3 RARS. One RARS case had a trisomy 8.
DNMT3A mutations were very recently reported in two series
of MDSs, including 62 RAEB cases
6 and 150 cases of various
subclasses.
7 In the RAEB series,
6 3 cases (4.8%) were mutated.
In the second series,
7 12 patients had DNMT3A mutations (8%).
These results show that, in chronic myeloid diseases, TET2
mutations are prominent, whereas IDH1/2 and DNMT3A are
less frequent. In MPNs, we did not ﬁnd any IDH mutation;
previous works had found that only 4% of PMF cases and few
PV and ET were mutated in IDH1/2.
8,9 IDH1/2 mutations are
also rare in MDSs, except in some subclasses such as MDSs with
del(5q) or trisomy 8.
5,10,11 Only six cases were mutated in
DNMT3A in our whole series of chronic cases. Overall, IDH1/2
and DNMT3A mutations are therefore more a feature of AMLs,
especially primary AMLs with normal karyotype and intermedi-
ate prognosis.
2,3 This suggests that mutations in TET2, IDH1/2
and DNMT3A, although potentially all functionally linked to
DNA methylation, may not be equivalent events in the initiation
of leukemogenesis; TET2 mutation could be more efﬁcient in
triggering the process. In our series, mutations of the three genes
were mutually exclusive, whereas DNMT3A mutations have
been found to be associated with TET2 or IDH1/2 mutations in
AMLs.
2 This may just be because of a low number of mutated
samples in chronic cases. However, this may also suggest that
IDH1/2 and DNMT3A mutations may participate, although less
frequently than TET2, to the initial phases of the disease. This
may be in collaboration with speciﬁc cooperating alterations
such as trisomy 8 or del(5q).
All our DNMT3A-mutated MDSs were low-risk RA/RARS
cases. The DNMT3A Arg882 amino-acid residue, which is a
mutation hotspot in AMLs,
1–3 was only mutated once in our
series of MPNs (in a PMF) and it was not mutated in our series of
MDSs. In the reported RAEB series,
6 the three mutations affected
the Arg882 residue. In the other published series,
7 three out of
the four Arg882-mutated MDSs were RAEB/RAEB-T cases. The
DNMT3A mutations can occur in the various subclasses of
MDS. However, the Arg882 mutation may be more speciﬁc of
RAEB and/or aggressive cases, whereas mutations at the other
residues may have a different function and may be associated
with a different (milder?) phenotype.
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Table 1 Mutations in three DNA methylation-associated genes in
patients with chronic myeloid diseases
TET2
a IDH1/2
a DNMT3A
a Total
a
MPNs (N¼135) 12 (8.9) 0 2 (1.5) 14 (10.4)
MDSs (N¼66) 12 (18.2) 5 (7.6) 4 (6) 21 (31.8)
Total (N¼201) 24 (11.9) 5 (2.5) 6 (3) 35 (17.4)
Abbreviations: IDH1, isocitrate dehydrogenase 1; MDS, myelodys-
plastic syndrome; MPN, myeloproliferative neoplasm.
aPercentages are in parentheses.
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